Home / Companies / News /  DCGI gives nod to Mylan labs to manufacture remdesivir
Back

The Drug Controller General of India (DCGI) has granted permission to Mylan laboratories to manufacture and market the anti-viral drug remdesivir for 'restricted emergency use' on hospitalised COVID-19 patients, a senior government official said on Thursday.

Previously, DCGI had given approval to Cipla and Hetero to manufacture and market remdesivir. ANI had reported last month that the Central Drug Control Standard Organisation (CDCSO) office of DCGI had granted its permission to US based Gilead Sciences for marketing authorisation of its anti-viral drug remdesivir in India for 'restricted emergency use' on hospitalised COVID-19 patients.

Gilead had signed non-exclusive voluntary licensing agreements with five generic pharma firms -- Cipla, Jubilant Life Sciences, Hetero, BRD and Mylan to manufacture and distribute remdesivir, a potential antiviral therapy for COVID-19.

This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less

Recommended For You

Trending Stocks

×
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout